Belinda Lovelace

Also affiliated with Health Outcomes Solutions (United States), Health Economics and Outcomes Research (United Kingdom)

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study”.

Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study

Research and Practice in Thrombosis and Haemostasis(2023)10.1016/j.rpth.2023.102192

N/A

1.4DataRank · unranked

31 citations

Gregory J. Fermann, Mary J. Christoph, Bruce Koch, Eva Lesén, Hungta Chen +7 more

Derivation and validation of a composite scoring system (SAVED2) for prediction of unfavorable modified Rankin scale score following intracerebral hemorrhage

Frontiers in Neurology(2023)10.3389/fneur.2023.1112723

N/A

0DataRank · unranked

3 citations

Mauricio Concha, Bruce Koch, Belinda Lovelace, Mary J. Christoph, Alexander T. Cohen +1 more

Reply to “Letter to Dobesh et al. on lower mortality with andexanet alfa in factor Xa inhibitor–related major bleeding”

Research and Practice in Thrombosis and Haemostasis(2024)10.1016/j.rpth.2024.102429

N/A

0DataRank · unranked

0 citations

Gregory J. Fermann, Mary J. Christoph, Bruce Koch, Eva Lesén, Hungta Chen +7 more